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Background: Urinary tract infections (UTIs) are common drivers of antibiotic use. The minimal effective duration of
antibiotic therapy for UTIs is unknown, but any reduction is important to diminish selection pressure for antibiotic
resistance, costs, and drug-related side-effects. The aim of this study was to investigate whether an algorithm based
on procalcitonin (PCT) and quantitative pyuria reduces antibiotic exposure.
Methods: From April 2012 to March 2014, we conducted a factorial design randomized controlled open-label trial.
Immunocompetent adults with community-acquired non-catheter-related UTI were enrolled in the emergency
department of a tertiary-care 600-bed hospital in northwestern Switzerland. Clinical presentation was used to guide
initiation and duration of antibiotic therapy according to current guidelines (control group) or with a PCT-pyuria-based
algorithm (PCT-pyuria group).
The primary endpoint was overall antibiotic exposure within 90 days. Secondary endpoints included duration of the
initial antibiotic therapy, persistent infection 7 days after end of therapy and 30 days after enrollment, recurrence and
rehospitalizations within 90 days.
Results: Overall, 394 patients were screened, 228 met predefined exclusion criteria, 30 declined to participate, and 11
were not eligible. Of these, 125 (76% women) were enrolled in the intention-to-treat (ITT) analysis and 96 patients with
microbiologically confirmed UTI constituted the per protocol group; 84 of 125 (67%) patients had a febrile UTI, 28 (22%)
had bacteremia, 5 (4%) died, and 3 (2%) were lost to follow-up. Overall antibiotic exposure within 90 days was shorter
in the PCT-pyuria group than in the control group (median 7.0 [IQR, 5.0–14.0] vs. 10.0 [IQR, 7.0–16.0] days, P = 0.011) in
the ITT analysis. Mortality, rates of persistent infections, recurrences, and rehospitalizations were not different.
Conclusions: A PCT-pyuria-based algorithm reduced antibiotic exposure by 30% when compared to current guidelines
without apparent negative effects on clinical outcomes.
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Urinary tract infections (UTIs) are common drivers of
antibiotic use and hospitalizations. In the United States,
almost 10 million outpatients are diagnosed with UTIs
each year [1], and UTIs account for 16% of all infectious
disease-related hospitalizations and 6% of all infectious
disease-related deaths [2]. Despite various prevention
strategies, recurrent UTIs are very common [3].
Any reduction of antibiotic exposure is important to
diminish selection pressure for antibiotic resistance,
costs, and drug-related side-effects [4]. Current guide-
lines for antibiotic treatment duration of febrile UTI/
pyelonephritis largely reflect expert opinion [5-8], as
only few intervention studies compared different durations
[9-13]. Most studies in this regard were performed to
establish short-term therapy in uncomplicated simple
UTIs [14,15]. Motivated by the emerging antibiotic resist-
ance of uropathogens [16-18] and the ecological effects of
antibiotics, the minimal effective duration of antibiotic
therapy is being challenged [19], especially in the elderly,
in whom UTIs are often over diagnosed and therefore
over treated. The use of biomarkers might improve the
management of patients with UTIs [20].
The biomarker procalcitonin (PCT) was established
for antibiotic stewardship in respiratory tract infections
[21,22] and sepsis [23]. As an indicator for systemic
infections [24], it showed high prognostic value to pre-
dict bacteremia in patients with urosepsis [25]. In the
PRORATA trial, which documented a safe reduction of
antibiotic usage through a PCT-guided strategy in pa-
tients with sepsis, UTIs were the source of infection in
7% of patients [26]. In patients with lower UTIs, PCT
may need to be complemented with inflammatory surro-
gates of local infection such as pyuria. Normalization of
pyuria in the first days after initiation of therapy corre-
lated with a successful outcome in women with lower
UTIs [27]. Therefore, we assumed that an algorithm
based on PCT and pyuria could safely reduce the dur-
ation of antibiotic therapy in patients with UTIs.
Methods
Design overview
We conducted an investigator-initiated, single-center,
factorial design, randomized controlled (1:1) and open-
label trial. Herein, we focus on the efficacy of an algo-
rithm based on clinical symptoms, PCT, and pyuria to
safely reduce the duration of antibiotic therapy compared
to current guidelines [6,15,28]. Details of the full trial de-
sign and methods have been published elsewhere [29].
The trial was conducted in accordance with the ethical
principles of the Helsinki Declaration. The local ethical
review committee of the Canton Aargau, Switzerland,
approved the study protocol. All patients or their next-
of-kin provided written informed consent.Setting and participants
From April 2012 to March 2014, we screened all con-
secutive immunocompetent adults with community-
acquired non-catheter-related UTIs as the main diagnosis
presenting to the emergency department of the cantonal
hospital of Aarau, a tertiary-care 600-bed hospital in
northwestern Switzerland.
A UTI was defined by at least one clinical symptom
(temperature ≥38.0°C, urinary urgency, dysuria, supra-
pubic pain, flank pain, costovertebral angle tender-
ness, nausea, and vomiting) and one urinary criterion
(pyuria >20 leukocytes/μL, obtained by flow cytometry
UF1000i (Sysmex) [27,30], and/or evidence of nitrite).
Presence of flank pain, costovertebral angle tenderness,
and/or a body temperature ≥38.0°C defined a ‘febrile
UTI/pyelonephritis’; otherwise, patients were consid-
ered to have a ‘simple UTI’. The criteria for a ‘com-
plicated UTI’ included any patient of at least 70
years, male gender, duration of symptoms of more
than 7 days, previous antibiotic therapy within 30
days, at least two prior UTIs in the last 6 months or
at least three during the last 12 months, any urologic
intervention within 30 days, functional or anatomic ab-
normality, diabetes mellitus, or immunosuppressive ther-
apy; otherwise it was referred to as an ‘uncomplicated
UTI’.
Patients were excluded if they presented with other in-
fections that required antibiotic therapy or had been
treated with antibiotics within 48 hours before presen-
tation; pregnancy; prostatitis defined as painful digital
rectal examination, a prostate-specific antigen value
of >4 ng/mL or ≥2× baseline before infection; foreign
bodies within the urinary tract; endovascular prostheses;
non-endovascular prostheses within 6 months after im-
plantation; insufficient language skills with no possibility
for translation; foreseeable non-compliance for follow-
up, e.g., current drug abuse; severe immunodeficiency:
neutrophils <500/μL, CD4 cells <350/μL in patients with
HIV-infection, leukemia, lymphoma, myeloma, cytotoxic
medications, hemodialysis, transplant patients; or life-
threatening medical comorbidities leading to possible
imminent death.
Randomization and interventions
The allocation of patients to either the PCT-pyuria
group or the control group was based on a pre-specified
computer generated randomization list and was con-
cealed on the study website.
Clinical presentation without (control group) or with
PCT and pyuria (PCT-pyuria group) was used to guide
initiation and duration of antibiotic therapy. The choice
of antibiotics and the minimal duration of therapy were
based on recent guidelines [6,15]. The algorithm is pre-
sented in Figure 1.
Figure 1 Algorithm for procalcitonin (PCT) and pyuria-guided therapy. TMP-SMX, Trimethoprim-sulfamethoxazole; NSAIDs, Non-steroidal
anti-inflammatory drugs; eGFR, Estimated glomerular filtration rate with Modification of Diet in Renal Disease Study equation.
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[31], trimethoprim-sulfamethoxazole (800/160 mg twice
daily) for estimated glomerular filtration rates (eGFR)
30 to 59 mL/min/1.73 m2 or ciprofloxacin (250 mg
twice daily) for eGFR <30 mL/min/1.73 m2. In the
PCT-pyuria group, patients with uncomplicated sim-
ple UTIs were planned to receive only non-steroidal
anti-inflammatory drugs (NSAIDs) for 3 days regard-
less of PCT-values [32,33].
For febrile UTIs/pyelonephritis, ciprofloxacin was
chosen as standard oral treatment for better comparabil-
ity with recent studies (500 mg orally twice daily,
respectively ciprofloxacin 250 mg orally twice daily for
eGFR <30 mL/min/1.73 m2), if intravenous therapy was
necessary ceftriaxone (2 g once daily) was chosen. When
known, antibiotic resistance profiles of prior or current
pathogens were taken into account and antibiotic ther-
apy was adjusted.
In inpatients in the PCT-pyuria group, antibiotic dur-
ation was based on absolute PCT-values and relativedecreases of PCT-levels, as well as pyuria. PCT and py-
uria were measured on admission in all patients; in
hospitalized patients, the measurements were continued
every other day till the end of antibiotic therapy. For
outpatients in the PCT-pyuria group, antibiotic duration
was calculated according to absolute values of PCT at
baseline. In the control group, antibiotic therapy dura-
tions were recommended based on current guidelines
[6,15] (Figure 1).
Urinalysis and urine culture with an antibiotic resist-
ance profile were performed on admission. In patients
with febrile UTI, blood cultures were taken prior to
administration of antibiotics.
To determine microbiological cure and recurrence
rates urinalysis and urine culture were performed on day
7 after end of therapy and day 30 after enrollment.
Patients were instructed in collection of midstream urine
for urinalysis and urine culture. These urine specimens
were sent by mail and reached the laboratory within
48 hours.
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All endpoints were assessed at discharge from hospital
and 30 and 90 days after enrollment through standard-
ized telephone interviews by blinded members of the
study team.
The primary endpoint was overall antibiotic exposure
within 90 days. Each day of antibiotic therapy for
any indication was counted as a full day of antibiotic
exposure.
Secondary endpoints included duration of the initial
antibiotic therapy; overall rate of recurrence, defined as
any re-treated UTI; overall rate of rehospitalization for
any cause within 90 days after enrollment; rate of per-
sistent infection 7 days after end of therapy, defined as
recovery of the initial uropathogen in the returned urine
culture plus pyuria >20 leucocytes/μL in the concomi-
tant urinalysis; and rate of persistent symptomatic infec-
tion 30 days after enrollment, defined as recovery of the
initial uropathogen in the returned urine culture plus
pyuria >20 leucocytes/μL in the concomitant urinaly-
sis plus symptoms of an UTI in the 30 days phone
interview.
All patients with positive urine cultures and pyuria in
the follow-up samples were contacted by phone by
members of the study team and advised to visit a general
practitioner or an emergency room. The laboratory
results were sent to the primary care providers when
available, but no further guidance was given as to
whether to prescribe an antibiotic.
Any serious adverse event, rehospitalization for any
cause, recurrence, or death of any cause within 90 days
after enrollment were monitored by the data safety and
monitoring board, which consisted of three independ-
ent experts in infectious diseases, nephrology, and
epidemiology.
Statistical analysis
The sample size was calculated assuming that duration
of antibiotic therapy would be two days shorter in the
PCT-pyuria group (8 days, standard deviation ±5) than
in the control group (10 days, standard deviation ±5).
Accordingly, 99 patients per arm would provide an 80%
power at the 5% alpha level [29].
The primary analysis was performed including all ran-
domized patients following an intention-to-treat (ITT)
principle. The per-protocol (PP) analysis was performed
in a defined population with microbiologically confirmed
UTI and without patients who violated inclusion or
exclusion criteria or were lost to follow-up. If the initial
urine culture was missing, sterile, or contaminated but a
uropathogen was isolated in concomitantly withdrawn
blood cultures, the patients were still included in the PP
analysis. We used predefined urine culture cut-offs for
significance [29].As the study was conceived in a two-by-two factorial
design, we checked for interaction between the two
randomization arms. As there was no evidence for inter-
action, the second randomization (proadrenomedullin-
assisted site of care decision [29]) was no longer
considered for this analysis.
Discrete variables were expressed as counts (percentage);
continuous variables as medians and interquartile range,
unless stated otherwise. For the analysis of the primary
endpoint of antibiotic exposure, we used the Mann–
Whitney U test for similarly shaped not normally
distributed continuous data. In sensitivity analysis, we
also used median regression to model the primary end-
point and adjusted the analysis for bacteremia. Logistic
regression analyses of persistent infection, recurrence,
and rehospitalization rates were performed to assess
safety endpoints. Since this was a feasibility study we
did not plan to have enough power for non-inferiority
testing.
Results
We screened 394 patients, of whom 269 were not eli-
gible due to the exclusion criteria, patient refusal, or
other reasons. Thus, 125 patients were enrolled in the
ITT analysis and 3 (2%) patients were lost to follow-up.
As predefined, 96 (77%) patients with microbiologically
confirmed UTIs and no protocol violations constituted
the PP analysis (Figure 2).
In five patients, the final diagnosis was retrospectively
different from a UTI: one patient with an infected kid-
ney cyst with Klebsiella oxytoca in blood cultures and
two patients with prostatitis with Staphylococcus aureus
in blood and urine cultures and with Escherichia coli
in urine culture, respectively, received prolonged
courses of antibiotics. One patient with severe sepsis
due to Staphylococcus aureus endocarditis died dur-
ing the initial hospitalization, and another patient
was diagnosed with fibromyalgia syndrome as explan-
ation for costovertebral angle tenderness and had a
sterile urine culture.
The baseline characteristics were generally well-
balanced except for the distribution of patients with
bacteremia, namely 19 (30%) in the control group
and 9 (15%) in the PCT-pyuria group (P = 0.045;
Table 1); 95 (76%) of the 125 patients were women
and 84 (67%) had a febrile UTI. The median age was
73 years (range, 19–96 years); 35 (28%) were treated
as outpatients.
Escherichia coli was identified in 72% of urine and
blood culture isolates (Table 2). Ciprofloxacin and
trimethoprim-sulfamethoxazole resistance in E. coli were
12% and 22%, respectively. In the PP analysis, the first-
line antibiotic therapy was efficacious in 44% to 100%, as
presented in Table 3.
Figure 2 Flow diagram of patients in trial.
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The overall antibiotic exposure within 90 days was
shorter in the PCT-pyuria group, both in the ITT ana-
lysis (7.0 vs. 10.0 days, P = 0.011) and in the PP analysis
(7.0 vs. 10.0 days, P = 0.025) groups. In subgroup ana-
lyses, PCT-pyuria led to shorter antibiotic therapies in
women (7.0 vs. 10.0 days, P = 0.022) and in patients with
complicated febrile UTI/pyelonephritis (7.5 vs. 11.0 days,
P = 0.002); for male patients, the difference did not reach
statistical significance (9.0 vs. 16.0 days, P = 0.062;
Table 4). The statistical analysis for predefined sub-
groups uncomplicated simple UTI, complicated simple
UTI, and uncomplicated febrile UTI/pyelonephritis was
limited by small numbers.
Secondary endpoint
The initial antibiotic therapy was shorter in the PCT-
pyuria group both in the ITT and PP analysis. Thisapplies to all subgroup analyses except for patients with
uncomplicated simple UTI (n = 8; Table 4).
Safety outcomes
The clinical recurrence rate and rehospitalization rates
within 90 days were similar in both groups (Table 5).
Overall, five (4%) patients died, one in the PCT-pyuria
group and four in the control group (Table 5). Safety
outcomes were similar between the PCT-pyuria and the
control group also within the subgroups of uncompli-
cated simple UTI, complicated simple UTI, uncompli-
cated febrile UTI/pyelonephritis, and complicated febrile
UTI/pyelonephritis (Table 5).
The rate of persistent infection (6% in the control
group vs. 6% in the PCT-pyuria group in ITT analysis)
and of new infections 7 days after end of therapy were
similar in both groups (6% in the control group vs.
6% in the PCT-pyuria group in ITT analysis). The
Table 1 Baseline characteristics by randomization group
Control group PCT/Pyuria group P valuea
n 64 61
Demographics
Age, median (IQR), y 75 (51–80) 71 (44–81) 0.65
Females, n (%) 52 (81%) 43 (70%) 0.16
Charlson comorbidity index, median (IQR) 4 (1-7) 3 (0-6) 0.20
Clinical history, n (%)
Dysuria 27 (42%) 29 (48%) 0.55
Urinary urgency 27 (43%) 22 (36%) 0.44
Frequent urination 23 (36%) 24 (39%) 0.69
Flank pain 20 (31%) 21 (34%) 0.71
Clinical findings, median (IQR)
Confusion, n (%) 16 (25%) 13 (21%) 0.63
Body temperature, °C 37.7 (36.9–38.6) 38.2 (37.0–39.0) 0.20
Systolic blood pressure, mm Hg 128 (110–145) 120 (108–135) 0.055
Diastolic blood pressure, mm Hg 69 (60–80) 70 (60–79) 0.85
Respiratory rate, breaths/min 16 (15–20) 16 (14–18) 0.18
Laboratory findings, median (IQR)
Leukocyte count, × 109cells/L 10.77 (7.83–14.34) 12.28 (9.18–15.65) 0.12
C-reactive protein, mg/L 34 (9–142) 44 (7–131) 0.84
PCT, μg/L 0.20 (0.08–1.34) 0.32 (0.11–1.32) 0.68
PCT ≥0.25 μg/L, n (%) 29 (45%) 33 (54%) 0.33
Serum creatinine, μmol/L 100 (77–136) 93 (74–117) 0.60
Blood urea nitrogen, mmol/L 6.5 (4.9–10.2) 6.3 (4.6–9.3) 0.64
Bacteremic patients, n (%) 19 (30%) 9 (15%) 0.045
Final diagnosis, n (%)
Uncomplicated simple UTI 6 (9%) 2 (3%) 0.36
Complicated simple UTI 12 (19%) 16 (26%)
Uncomplicated febrile UTI/pyelonephritis 8 (13%) 9 (15%)
Complicated febrile UTI/pyelonephritis 34 (53%) 33 (54%)
Other final diagnosisb 4 (6%) 1 (2%)
Complicated UTI 46 (72%) 49 (80%) 0.27
Male patients 12 (19%) 18 (30%) 0.16
Patients older than or equal 70 years 35 (55%) 34 (56%) 0.91
Patients with symptoms longer than 7 days 10 (16%) 7 (12%) 0.50
Patients with antibiotic therapy in the last 30 days 5 (8%) 10 (16%) 0.14
Patients with diabetes 16 (25%) 8 (13%) 0.092
Patients with recurrent UTIs 5 (8%) 9 (15%) 0.22
Patients with urologic interventions in the last 30 days 3 (5%) 2 (3%) 0.69
Patients with anatomic abnormalities 2 (3%) 5 (8%) 0.22
Patients with immunosuppression 0 2 (3%) 0.14
Patients from long-term healthcare facilities 5 (8%) 4 (7%) 0.79
Hospitalized patients, n (%) 45 (70%) 45 (74%) 0.67
aχ2 test for categorical variables, 2-sample t-test for continuous variables.
bProstatitis (n = 2), infected kidney cyst (n = 1), endocarditis (n = 1), fibromyalgia syndrome (n = 1).
IQR, Interquartile range; y, Years.
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Table 3 Initial antibiotic therapy by randomization group
Control group PCT/Pyuria group
All patients
(intention-to-treat)
(n = 64) (n = 61)
First-line antibiotic therapy
Ciprofloxacin 25 (39%) 20 (33%)
Ceftriaxon 18 (28%) 18 (30%)
TMP-SMZ 9 (14%) 15 (25%)
Fosfomycin 6 (9%) 3 (5%)
Amoxicillin-Clavulanate 5 (8%) 1 (2%)
Other 1 (2%) 3 (5%)
NSAIDS 0 1 (2%)
Second-line antibiotic
therapy
Ciprofloxacin 10 (16%) 15 (25%)
Ceftriaxon 4 (6%) 4 (7%)
TMP-SMZ 4 (6%) 3 (5%)
Amoxicillin-Clavulanate 4 (6%) 3 (5%)
Other 3 (5%) 5 (8%)
Per-protocol population (n = 52) (n = 44)
First-line antibiotic therapy




















Other 1 (2%) 2 (4%)
NSAIDS 0 1 (2%)
Second-line antibiotic
therapy
















Other 5 (10%) 3 (7%)
TMP-SMX, Trimethoprim-sulfamethoxazole; NSAIDs, Non-steroidal
anti-inflammatory drugs.
Table 2 Microbiological results at baseline





All patients (intention-to-treat) (n = 64) (n = 61)
Missing urine cultures 2 (3%) 8 (13%)
Sterile urine cultures 4 (6%) 4 (7%)
Contaminated urine cultures 6 (9%) 3 (5%)
Urine cultures with bacterial growth 52 (82%) 46 (75%)
Total no. of isolatesa 53 52
Gram-negative uropathogen
Escherichia coli 37/53 (70%) 39/52 (75%)
Klebsiella pneumoniae 6/53 (11%) 3/52 (6%)
Citrobacter koseri 0 1/52 (2%)
Pseudomonas aeruginosa 0 1/52 (2%)
Proteus mirabilis 0 1/52 (2%)
Gram-positive uropathogen
Enterococcus faecalis 3/53 (6%) 6/52 (12%)
Aerococcus urinae 1/53 (2%) 0
Non uropathogen
Staphylococcus aureus 3/53 (6%) 0
Lactobacillus speciesb 2/53 (4%) 0
Granulicatella adiacens 0 1/52 (2%)
Salmonella species 1/53 (2%) 0





All patients (intention-to-treat) (n = 64) (n = 61)
Blood samples for culture obtained 44 (69%) 44 (72%)
No. (%) of contaminated blood cultures 2/44 (5%) 2/44 (5%)
Coagulase-negative staphylococci 2/44 (5%) 1/44 (2%)
Propionibacterium acnes 0 1/44 (2%)
No. (%) of positive blood cultures 19/44 (43%) 9/44 (20%)
Gram-negative uropathogen
Escherichia coli 14/19 (74%) 9/9 (100%)
Klebsiella oxytoca 1/19 (5%)c 0
Gram-positive uropathogen
Enterococcus faecalis 1/19 (5%) 0
Non uropathogen
Staphylococcus aureus 2/19 (11%)c 0
Lactobacillus species 1/19 (5%) 0
aTwo isolates in five cultures, three isolates in one culture.
bLactobacillus species was not a classical uropathogen but in one case
confirmed by concomitant positive blood cultures with Lactobacillus species
(4/4 samples).
cThree patients not included in the per protocol analysis with final diagnosis
other than UTI: Klebsiella oxytoca in one patient with infected kidney cyst,
Staphylococcus aureus in one patient with endocarditis, and one patient
with prostatitis.
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on day 7 after end of therapy are presented in Table 6.
The rate of persistent symptomatic infection 30 days
after enrollment was not significantly different between
Table 4 Antibiotic exposure by randomization group with subgroup analysis
Control group PCT/Pyuria group P valuea
Median (IQR), days Median (IQR), days
All patients (intention-to-treat) (n = 64) (n = 61)
Duration of initial antibiotic therapy 10.0 (7.0–11.0) 6.0 (4.0–8.0) <0.001
Antibiotic exposure within 90 days 10.0 (7.0–16.0) 7.0 (5.0–14.0) 0.011
Per-protocol population (n = 52) (n = 44)
Duration of initial antibiotic therapy 10.0 (7.0–11.0) 6.0 (4.0–7.0) <0.001
Antibiotic exposure within 90 days 10.0 (7.5–16.0) 7.0 (5.0–14.5) 0.025
Female patients (n = 52) (n = 43)
Duration of initial antibiotic therapy 9.0 (7.0–10.5) 5.0 (4.0–7.0) <0.001
Antibiotic exposure within 90 days 10.0 (7.0–14.0) 7.0 (4.0–13.0) 0.022
Male patients (n = 12) (n = 18)
Duration of initial antibiotic therapy 11.0 (10.5–12.0) 6.5 (5.0–9.0) 0.003
Antibiotic exposure within 90 days 16.0 (11.0–21.0) 9.0 (6.0–19.0) 0.062
Inpatients (n = 45) (n = 45)
Duration of initial antibiotic therapy 10.0 (8.0–11.0) 7.0 (5.0–9.0) <0.001
Antibiotic exposure within 90 days 11.0 (10.0–18.5) 8.5 (6.5–16.5) 0.023
Uncomplicated simple UTI (n = 6) (n = 2)
Duration of initial antibiotic therapy 1.0 (1.0–1.0) 0.5 (0.0–1.0) 0.127
Antibiotic exposure within 90 days 1.0 (1.0–1.0) 4.0 (1.0–7.0) 0.513
Complicated simple UTI (n = 12) (n = 16)
Duration of initial antibiotic therapy 7.0 (7.0–9.0) 4.0 (2.5–5.5) 0.005
Antibiotic exposure within 90 days 10.0 (8.0–12.0) 5.5 (3.0–14.0) 0.083
Uncomplicated febrile UTI/pyelonephritis (n = 8) (n = 9)
Duration of initial antibiotic therapy 7.0 (7.0–7.5) 4.0 (4.0–6.0) 0.009
Antibiotic exposure within 90 days 7.0 (7.0–10.5) 6.5 (4.0–11.0) 0.238
Complicated febrile UTI/pyelonephritis (n = 34) (n = 33)
Duration of initial antibiotic therapy 10.5 (10.0–11.0) 7.0 (6.0–9.0) <0.001
Antibiotic exposure within 90 days 11.0 (10.0–18.0) 7.5 (6.5–13.5) 0.002
aMann–Whitney U-test.
IQR, Interquartile range.
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both groups, OR, 1.07; 95% CI, 0.14–7.90; P = 0.95
in ITT analysis). There were no symptomatic infec-
tions with new organisms 30 days after enrollment
(Table 7).
Bacteremic patients
As the distribution of patients with bacteremia was not
well balanced between the two study arms we performed
a stratified analysis of the primary and secondary out-
comes for bacteremic and non-bacteremic patients
(Additional file 1: Table S1). As a sensitivity analysis for
the primary endpoint we also performed median regres-
sion analysis adjusted for bacteremia. Adjusted results
were robust and showed a significant reduction in anti-
biotic exposure (coefficient, −3.0; 95% CI, −0.6 to −5.4;P = 0.015). Among bacteremic patients, the initial anti-
biotic therapy was shorter in the PCT-pyuria group
(7.0 vs. 11.0 days, P ≤0.001); overall antibiotic exposure
within 90 days was not different. The recurrence
rate was higher in the PCT-pyuria group (56% vs.
16% in the control group, OR, 6.67; 95% CI, 0.04–
1.10; P = 0.039) but rehospitalization rates were not
significantly different.
The rates of persistent infection 7 days after end of
therapy were similar in both groups (13% in the PCT-
pyuria group vs. 6% in the control group, OR, 2.14; 95%
CI, 0.12–39.47; P = 0.61).
There were two symptomatic infections with new or-
ganisms 7 days after end of therapy and one persistent
symptomatic infection 30 days after enrollment in the
control group.
Table 5 Rates of adverse outcomes
Control group PCT/Pyuria group Odds ratio 95% CI P valuea
All patients (intention-to-treat) (n = 64) (n = 61)
Recurrence 14/63 (22%) 15/59 (25%) 1.19 0.52–2.75 0.68
Rehospitalization 17/63 (27%) 15/59 (25%) 0.92 0.41–2.07 0.85
Death 4/63 (6%) 1/59 (2%) 0.25 0.03–2.30 0.22
Per-protocol population (n = 52) (n = 44)
Recurrence 11/52 (21%) 14/44 (32%) 1.74 0.69–4.36 0.24
Rehospitalization 13/52 (35%) 13/44 (41%) 1.26 0.51–3.10 0.62
Death 1/52 (2%) 0
Inpatients (n = 45) (n = 45)
Recurrence 11 (25%) 13 (30%) 1.26 0.49–3.22 0.63
Rehospitalization 15 (34%) 13 (30%) 0.81 0.28–0.96 0.65
Uncomplicated simple UTI (n = 6) (n = 2)
Recurrence 1/6 (17%) 1/2 (50%) 5.00 0.15–166.59 0.37
Rehospitalization 1/6 (17%) 1/2 (50%) 5.00 0.15–166.59 0.37
Complicated simple UTI (n = 12) (n = 16)
Recurrence 3/11 (27%) 6/16 (38%) 1.60 0.30–8.49 0.58
Rehospitalization 2/11 (18%) 6/16 (38%) 2.70 0.43–16.94 0.29
Uncomplicated febrile UTI/pyelonephritis (n = 8) (n = 9)
Recurrence 1/8 (13%) 2/8 (25%) 2.33 0.17–32.58 0.53
Rehospitalization 2/8 (25%) 1/8 (13%) 0.43 0.03–5.98 0.53
Complicated febrile UTI/pyelonephritis (n = 34) (n = 33)
Recurrence 8/34 (24%) 6/32 (19%) 0.75 0.23–2.47 0.64
Rehospitalization 11/34 (32%) 7/32 (22%) 0.59 0.19–1.77 0.34
aLogistic regression analysis.
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As UTIs are one of the most common indications
for antibiotic therapy, the impact of a reduction of
treatment duration could be enormous. This study
provides evidence that guidance of antibiotic therapy
in patients with a UTI by a PCT-pyuria algorithm
for antibiotic guidance is feasible. The implementa-
tion of an algorithm into clinical workflows is prac-
ticable as shown by our group in respiratory tract
infections [34]. The efficacy of this approach is evi-
denced by the 90 day observation period for the pri-
mary endpoint, which included both the initial and
any subsequent antibiotic treatments.
Overall and in most subgroups (except for the small
subgroup of patients with uncomplicated simple UTIs),
the PCT-pyuria algorithm led to shorter initial duration
of antibiotic therapy. The tested algorithm can help to
determine the optimal length of antibiotic therapy and
avoid antibiotic overuse.
There was an imbalance in randomization of eight
patients with uncomplicated simple UTI with only
two being randomized to the PCT-pyuria group.Since all six patients in the standard guidelines group
were treated according to our algorithm with single-
dose fosfomycin, the median duration of the initial
antibiotic therapy in this subgroup was similar be-
tween both groups.
Only one patient in the PCT-pyuria group, who re-
lapsed with urosepsis and had to be hospitalized for
3 days and treated with intravenous antibiotics, was
initially treated with NSAIDs according to the study
protocol. Given the small number of outpatients, the
safety of NSAIDs for simple uncomplicated UTIs
cannot be determined based on our study. Despite
recent data with promising results for this approach
[32,33], a recent review [13] emphasized the need for
immediate antimicrobial therapy rather than delayed
treatment or symptomatic management with ibupro-
fen alone.
Patients with complicated febrile UTI were older and
had multiple comorbidities. Especially in this population
with the highest disease burden, in whom the longest
antibiotic therapy is recommended by current guide-
lines, our algorithm proved to be effective.
Table 6 Microbiological outcome 7 days after end of therapy
n (%) Control group PCT/Pyuria group Odds ratio 95% CI P valuea
All patients (intention-to-treat) (n = 64) (n = 61)
Missing urinalysis 10/64 (16%) 8/61 (13%) 0.82 0.30–2.22 0.69
Missing urine cultures 8/64 (13%) 8/61 (13%) 1.06 0.37–3.02 0.92
Sterile urine cultures 19/56 (34%) 20/53 (38%) 1.18 0.54–2.58 0.68
Contaminated urine culturesb 25/56 (45%) 16/53 (30%) 0.54 0.24–1.18 0.12
Urine cultures with pathogenc 12/56 (21%) 17/53 (32%) 1.73 0.73–4.09 0.21
Colonizations 6/53 (11%) 8/51 (16%) 1.46 0.47–4.54 0.52
Infectionsd 6/53 (11%) 8/51 (16%) 1.46 0.47–4.54 0.52
Persistence of initial pathogenc 3/56 (5%) 4/51 (8%) 1.50 0.32–7.07 0.61
Persistent colonization 0 1/51 (2%)
Persistent infectiond 3/53 (6%) 3/51 (6%) 1.04 0.20–5.42 0.96
New organismc 9/56 (16%) 11/51 (22%) 1.44 0.54–3.81 0.47
Colonizations 6/53 (11%) 7/49 (14%) 1.31 0.41–4.19 0.65
Infectionsd 3/53 (6%) 3/49 (6%) 1.09 0.21–5.66 0.92
n (%) Control Group PCT/ Pyuria Group
Total no. of isolates 13 18
Gram-negative uropathogen
Escherichia coli 3/13 (23%) 3/18 (17%)
Klebsiella pneumoniae 1/13 (8%) 1/18 (6%)
Gram-positive uropathogen
Enterococcus faecalis 6/13 (46%) 11/18 (61%)
Enterococcus faecium 1/13 (8%) 1/18 (6%)
Staphylococcus saprophyticus 1/13 (8%) 0
Non uropathogen
Lactobacillus speciesb 1/13 (8%) 1/18 (6%)
Candida albicans 0 1/18 (6%)
aLogistic regression analysis.
bLactobacillus species were considered as contaminants.
cIn case of contaminated (n = 1 in PCT/Pyuria group) initial urine culture any uropathogen was considered as new organism, in case of missing (n = 2 in PCT/ Pyuria group)
initial urine culture the uropathogen was not attributed to persistent or new organism group.
dInfection was assumed if pyuria (>20 leukocytes/μL) was present in concomitant urinalysis.
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ference in rates of persistent infection was shown at
7 days after end of therapy or at 30 days after enroll-
ment. The slightly higher, but non-significant, rate of
bacteriuria and asymptomatic infection in the PCT-
pyuria group should not be viewed as an unsuccessful
treatment. There is vast evidence that asymptomatic
bacteriuria should not be treated [35]. In fact, asymp-
tomatic bacteriuria might be protective against future
development of pyelonephritis, as elegantly shown in a
prospective Italian study of young women with asymp-
tomatic bacteriuria, who benefited from symptomatic
treatment versus antibiotics [36]. There is evidence that
in older patients with isolated non-specific signs or non-
infectious symptoms, such as delirium, urine testing and
subsequent antibiotic therapy should not be ordered [37].Furthermore, the follow-up mid-stream urine cultures
in the PCT-pyuria group yielded in the majority of cases
Enterococcus faecalis (Table 2), which has recently been
shown to have a low positive predictive value for uro-
pathogen growth in the bladder [38].
The antibiotics chosen in our algorithm, derived from
international guidelines, should not deter from the neces-
sity to adapt antibiotic choices to local epidemiology and
resistance data [9]. In Switzerland, 18.5% of Escherichia coli
were resistant to fluoroquinolones in 2013, compared to
22.3% in the European Union in 2012 [39,40].
A major strength was the innovative study design with
antibiotic guidance based on the combination of the
systemic and local response against a control group re-
ceiving antibiotic therapy according to the low end of
currently recommended guidelines.
Table 7 Microbiological and clinical outcome 30 days after enrollment
n (%) Control group PCT/Pyuria group Odds ratio 95% CI P valuea
All patients (intention-to-treat) (n = 64) (n = 61)
Missing urinalysis 10/64 (16%) 9/61 (13%) 0.93 0.35–2.48 0.89
Missing urine cultures 14/64 (22%) 11/61 (18%) 0.79 0.33–1.90 0.59
Sterile urine cultures 19/50 (38%) 8/50 (16%) 0.31 0.12–0.80 0.02
Contaminated urine culturesb 20/50 (40%) 26/50 (52%) 1.63 0.74–3.59 0.23
Urine cultures with pathogenc 11/50 (22%) 16/50 (32%) 1.67 0.68–4.08 0.26
Colonizations 3/50 (6%) 3/49 (6%) 1.02 0.20–5.33 0.98
Infectionsd 8/50 (16%) 13/49 (27%) 1.90 0.71–5.09 0.20
Symptomatic infections 2/50 (4%) 3/49 (6%) 1.57 0.25–9.80 0.63
Persistence of initial pathogenc 6/50 (12%) 8/48 (17%) 1.47 0.47–4.59 0.51
Persistent colonizations 1/50 (2%) 1/47 (2%) 1.07 0.06–17.53 0.97
Persistent infectionsd 5/50 (10%) 7/47 (15%) 1.58 0.46–5.36 0.47
Persistent symptomatic infectionsd 2/50 (4%) 2/47 (4%) 1.07 0.14–7.90 0.95
New organismc 5/50 (10%) 6/48 (13%) 1.29 0.37–4.53 0.70
Colonizations 2/50 (4%) 2/47 (4%) 1.07 0.14–7.90 0.95
Infectionsd 3/50 (6%) 4/47 (9%) 1.46 0.31–6.89 0.64
Symptomatic infectionsd 0 0
n (%) Control group PCT/Pyuria group
Total no. of isolatese 17 22
Gram-negative uropathogen
Escherichia coli 5/17 (29%) 7/22 (32%)
Klebsiella pneumoniae 2/17 (12%) 1/22 (5%)
Citrobacter koseri 1/17 (6%) 1/22 (5%)
Enterobacter cloacae 0 1/22 (5%)
Pseudomonas aeruginosa 0 1/22 (5%)
Gram-positive uropathogen
Enterococcus faecalis 5/17 (29%) 9/22 (41%)
Enterococcus faecium 1/17 (6%) 0
Staphylococcus saprophyticus 0 1/22 (5%)
Group B Streptococci 1/17 (6%) 0
Non-uropathogen
Staphylococcus aureus 1/17 (6%) 0
Coagulase-negative staphylococcib 0 1/22 (5%)
Lactobacillus speciesb 1/17 (6%) 1/22 (5%)
Streptococcus milleri 0 1/22 (5%)
aLogistic regression analysis.
bLactobacillus species and Coagulase-negative staphylococci were considered as contaminants.
cIn case of missing initial urine culture (n = 2 in the PCT/Pyuria group) any uropathogen was not attributed to persistent or new organism group.
dInfection was assumed if pyuria (>20 leukocytes/μL) was present in concomitant urinalysis.
eTwo isolates in nine cultures.
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Our study has the following limitations. First, the small
sample size due to slow recruitment and the heterogen-
eity of patients within the predefined subgroups limit
the power of the analysis, especially regarding safety
outcomes. Second, the follow-up mode by telephoneinterview and by urine samples which were returned by
mail harbors potential recall bias and underreporting,
which we tried to counteract by contacting the primary
care physician and by obtaining discharge letters of sub-
sequent hospitalizations. Third, the analysis of the recur-
rence rate in the subgroup of patients with bacteremia
Drozdov et al. BMC Medicine  (2015) 13:104 Page 12 of 13was limited due to the small numbers. Further studies
will have to clarify whether this algorithm needs to be
adapted for patients with bacteremia.
Conclusions
An algorithm based on PCT and pyuria significantly re-
duces antibiotic exposure when compared to current
guidelines without apparent negative effects on clinical
outcomes, especially in patients with complicated febrile
UTI. Further randomized controlled multi-center studies
with larger patient numbers are needed to confirm our
findings for all subgroups and to proof the feasibility in
other settings.
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